DK3773715T3 - Mirikizumab i behandlingen af colitis ulcerosa - Google Patents
Mirikizumab i behandlingen af colitis ulcerosa Download PDFInfo
- Publication number
- DK3773715T3 DK3773715T3 DK19722256.5T DK19722256T DK3773715T3 DK 3773715 T3 DK3773715 T3 DK 3773715T3 DK 19722256 T DK19722256 T DK 19722256T DK 3773715 T3 DK3773715 T3 DK 3773715T3
- Authority
- DK
- Denmark
- Prior art keywords
- mirikizumab
- treatment
- ulcerative colitis
- ulcerative
- colitis
- Prior art date
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title 1
- 201000006704 Ulcerative Colitis Diseases 0.000 title 1
- 229950009792 mirikizumab Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650314P | 2018-03-30 | 2018-03-30 | |
| PCT/US2019/024633 WO2019191464A1 (en) | 2018-03-30 | 2019-03-28 | Methods of treating ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3773715T3 true DK3773715T3 (da) | 2024-05-27 |
Family
ID=66429483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19722256.5T DK3773715T3 (da) | 2018-03-30 | 2019-03-28 | Mirikizumab i behandlingen af colitis ulcerosa |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12152072B2 (enExample) |
| EP (2) | EP4327866B1 (enExample) |
| JP (4) | JP7119114B2 (enExample) |
| KR (1) | KR102552693B1 (enExample) |
| CN (1) | CN111936165A (enExample) |
| AU (2) | AU2019243283C1 (enExample) |
| BR (1) | BR112020018099A2 (enExample) |
| CA (1) | CA3095297A1 (enExample) |
| DK (1) | DK3773715T3 (enExample) |
| EA (1) | EA202091989A1 (enExample) |
| ES (1) | ES2983809T3 (enExample) |
| FI (1) | FI3773715T3 (enExample) |
| HR (1) | HRP20240904T1 (enExample) |
| HU (1) | HUE067445T2 (enExample) |
| IL (2) | IL277514B2 (enExample) |
| LT (1) | LT3773715T (enExample) |
| MA (1) | MA52216B1 (enExample) |
| MD (1) | MD3773715T2 (enExample) |
| MX (1) | MX2020010269A (enExample) |
| MY (1) | MY202368A (enExample) |
| PL (1) | PL3773715T3 (enExample) |
| PT (1) | PT3773715T (enExample) |
| RS (1) | RS65661B1 (enExample) |
| SG (1) | SG11202009526RA (enExample) |
| SI (1) | SI3773715T1 (enExample) |
| TW (2) | TWI837532B (enExample) |
| UA (1) | UA128578C2 (enExample) |
| WO (1) | WO2019191464A1 (enExample) |
| ZA (1) | ZA202005388B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113874073A (zh) | 2019-05-23 | 2021-12-31 | 詹森生物科技公司 | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 |
| US20210253690A1 (en) * | 2020-02-14 | 2021-08-19 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody |
| CN115768466A (zh) | 2020-05-21 | 2023-03-07 | 詹森生物科技公司 | 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法 |
| JP7423815B2 (ja) * | 2020-10-20 | 2024-01-29 | セトラスホールディングス株式会社 | 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム |
| BR112023013444A2 (pt) * | 2021-01-06 | 2024-01-23 | Abbvie Deutschland | Métodos para tratar doença de crohn e colite ulcerativa |
| KR20240012469A (ko) * | 2021-05-20 | 2024-01-29 | 얀센 바이오테크 인코포레이티드 | Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법 |
| CA3219846A1 (en) * | 2021-05-28 | 2022-12-01 | Venkatesh Krishnan | Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis |
| EP4623001A1 (en) * | 2022-11-22 | 2025-10-01 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| AU2024236477A1 (en) | 2023-03-10 | 2025-09-11 | Eli Lilly And Company | Methods of treating ulcerative colitis |
| TW202500185A (zh) * | 2023-06-16 | 2025-01-01 | 大陸商信達生物製藥（蘇州）有限公司 | 重組抗白介素２３ｐ１９亞基抗體在治療炎症性腸病中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3501537A1 (en) * | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
| JP5193881B2 (ja) | 2005-12-29 | 2013-05-08 | セントカー・インコーポレーテツド | ヒト抗ｉｌ−２３抗体、組成物、方法および用途 |
| BRPI0807710B1 (pt) | 2007-02-23 | 2021-12-14 | Merck Sharp & Dohme Corp | Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica |
| US20110212104A1 (en) * | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| PT2635601T (pt) * | 2010-11-04 | 2016-09-27 | Boehringer Ingelheim Int | Anticorpos anti-il-23 |
| JOP20140049B1 (ar) | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
| US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| US20190269757A1 (en) * | 2018-03-05 | 2019-09-05 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
-
2019
- 2019-03-27 TW TW110139868A patent/TWI837532B/zh active
- 2019-03-27 TW TW108110767A patent/TWI744617B/zh active
- 2019-03-28 CA CA3095297A patent/CA3095297A1/en active Pending
- 2019-03-28 WO PCT/US2019/024633 patent/WO2019191464A1/en not_active Ceased
- 2019-03-28 RS RS20240698A patent/RS65661B1/sr unknown
- 2019-03-28 IL IL277514A patent/IL277514B2/en unknown
- 2019-03-28 EP EP23215626.5A patent/EP4327866B1/en active Active
- 2019-03-28 AU AU2019243283A patent/AU2019243283C1/en active Active
- 2019-03-28 LT LTEPPCT/US2019/024633T patent/LT3773715T/lt unknown
- 2019-03-28 MX MX2020010269A patent/MX2020010269A/es unknown
- 2019-03-28 ES ES19722256T patent/ES2983809T3/es active Active
- 2019-03-28 PT PT197222565T patent/PT3773715T/pt unknown
- 2019-03-28 MA MA52216A patent/MA52216B1/fr unknown
- 2019-03-28 HR HRP20240904TT patent/HRP20240904T1/hr unknown
- 2019-03-28 UA UAA202005571A patent/UA128578C2/uk unknown
- 2019-03-28 DK DK19722256.5T patent/DK3773715T3/da active
- 2019-03-28 JP JP2020552872A patent/JP7119114B2/ja active Active
- 2019-03-28 MY MYPI2020004942A patent/MY202368A/en unknown
- 2019-03-28 SI SI201930750T patent/SI3773715T1/sl unknown
- 2019-03-28 EP EP19722256.5A patent/EP3773715B1/en active Active
- 2019-03-28 CN CN201980023563.3A patent/CN111936165A/zh active Pending
- 2019-03-28 FI FIEP19722256.5T patent/FI3773715T3/fi active
- 2019-03-28 EA EA202091989A patent/EA202091989A1/ru unknown
- 2019-03-28 SG SG11202009526RA patent/SG11202009526RA/en unknown
- 2019-03-28 MD MDE20210135T patent/MD3773715T2/ro unknown
- 2019-03-28 BR BR112020018099-8A patent/BR112020018099A2/pt unknown
- 2019-03-28 IL IL312807A patent/IL312807B2/en unknown
- 2019-03-28 PL PL19722256.5T patent/PL3773715T3/pl unknown
- 2019-03-28 HU HUE19722256A patent/HUE067445T2/hu unknown
- 2019-03-28 US US16/981,915 patent/US12152072B2/en active Active
- 2019-03-28 KR KR1020207027982A patent/KR102552693B1/ko active Active
-
2020
- 2020-08-28 ZA ZA2020/05388A patent/ZA202005388B/en unknown
-
2022
- 2022-08-03 JP JP2022123689A patent/JP7331219B2/ja active Active
-
2023
- 2023-08-09 JP JP2023130117A patent/JP7571225B2/ja active Active
- 2023-10-11 AU AU2023248103A patent/AU2023248103A1/en active Pending
-
2024
- 2024-10-09 JP JP2024176901A patent/JP2025020134A/ja active Pending
- 2024-10-16 US US18/917,597 patent/US20250034243A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3773715T3 (da) | Mirikizumab i behandlingen af colitis ulcerosa | |
| HUS2500039I1 (hu) | Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra | |
| DK3743053T3 (da) | Anvendelse af cannabinoider i behandling af epilepsi | |
| DK3578547T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| DK3641819T3 (da) | Anvendelse af cannabidiol i behandling af tuberøst sklerosekompleks | |
| DK3554631T3 (da) | Behandling af patienter med ttfields med elektrodepositionerne optimeret under anvendelse af deformerbare skabeloner | |
| DK3562486T3 (da) | Anvendelse af sublingual dexmedetomidin til behandling af agitation | |
| DK3117310T3 (da) | Håndtering af behandling associeret med valgte arkitektoniske indretninger | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| DK3334422T3 (da) | Anvendelse af cannabidiolsyre i behandling af epilepsi | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3576738T3 (da) | Gaboxadolmonohydrat i behandling af tinnitus | |
| DK3638696T3 (da) | Anvendelse af anti-cd70-antistof argx-110 til behandling af akut myeloid leukæmi | |
| DK3204497T3 (da) | Terapeutisk hæmning af lactatdehydrogenase og midler dertil | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3464368T3 (da) | Anvendelse af et anti-pd-1-antistof i kombination med et anti-cd30- antistof i lymfombehandling | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom | |
| DK3102218T3 (da) | Behandling af topiske og systemiske bakterieinfektioner | |
| DK3706739T3 (da) | Anvendelse af riluzolprodrugs til behandling af ataksier | |
| DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
| DK3535511T3 (da) | Reduktion af mikrobiologisk vækst i rør |